Utidelone Plus Bevacizumab for ERBB2 -Negative Metastatic Breast Cancer and Active Brain Metastases: The U-BOMB Phase 2 Nonrandomized Clinical Trial

医学 贝伐单抗 转移性乳腺癌 内科学 实体瘤疗效评价标准 脑转移 临床终点 乳腺癌 肿瘤科 放射治疗 癌症 转移 临床试验 化疗 进行性疾病
作者
Min Yan,Huimin Lv,Xinlan Liu,Shusen Wang,Cuizhi Geng,Yuhua Song,Zhenzhen Liu,Limin Niu,Mengwei Zhang,Chengzheng Wang,Yajing Feng,Huiai Zeng,Huihui Sun,Jing Wang,Yufen Xiang,Li Tang,Rongguo Qiu
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:11 (8): 883-883 被引量:11
标识
DOI:10.1001/jamaoncol.2025.1694
摘要

Importance: Patients with ERBB2 (formerly HER2 or HER2/neu)-negative metastatic breast cancer (MBC) and brain metastases have poor prognosis, and effective treatment options are limited. Objective: To investigate the activity and safety of utidelone plus bevacizumab in patients with ERBB2-negative MBC and active brain metastases. Design, Setting, and Participants: This nonrandomized clinical trial was conducted at 5 hospitals in China. Adult patients with ERBB2-negative MBC who had untreated or progressive brain metastases were enrolled between May 5, 2022, and October 25, 2023. The data cutoff date was May 20, 2024; data were analyzed from September 15, 2022, to July 20, 2024. Interventions: Patients received bevacizumab (15 mg/kg on day 1) and utidelone (30 mg/m2 on days 1-5) every 3 weeks until disease progression or unacceptable toxic effects. Main Outcomes and Measures: The primary end point was central nervous system (CNS) objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Results: A total of 47 female patients (median age, 53 years [IQR, 45-59 years]) were recruited. Of these, 35 patients had untreated brain metastases and 12 had brain metastases that had progressed after local radiotherapy. The CNS ORR was 42.6% (95% CI, 28.3%-57.8%) per RECIST version 1.1 and 40.4% (95% CI, 26.4%-55.7%) per Response Assessment in Neuro-Oncology Brain Metastases criteria. The median follow-up duration was 11.0 months (range, 2.3-23.6 months). The median progression-free survival (PFS) was 7.7 months (95% CI, 5.6-9.7), median CNS-PFS was 10.6 months (95% CI, 8.4 months to not reached), and median overall survival was 15.1 months (95% CI, 12.0 months to not reached). The most common grade 3 or higher treatment-emergent adverse events were decreased lymphocyte count in 5 patients (10.6%) and decreased white blood cell count in 3 patients (6.4%). No serious or fatal adverse events occurred. Conclusions and Relevance: The findings of this nonrandomized clinical trial suggest the potential of utidelone plus bevacizumab for the treatment of patients with ERBB2-negative MBC and active brain metastases. This treatment approach warrants further validation in a randomized clinical trial. Trial Registration: ClinicalTrials.gov Identifier: NCT05357417.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
142857完成签到,获得积分10
刚刚
Una2030完成签到 ,获得积分10
4秒前
轻松香菇完成签到 ,获得积分10
5秒前
Jeffrey完成签到,获得积分10
6秒前
房杨完成签到,获得积分10
6秒前
七七完成签到 ,获得积分10
7秒前
怡然铭完成签到 ,获得积分10
8秒前
黄芪完成签到,获得积分10
12秒前
高山流水完成签到,获得积分10
13秒前
lingling00完成签到 ,获得积分10
14秒前
山野的雾完成签到 ,获得积分10
15秒前
沉静梦蕊完成签到,获得积分10
19秒前
枯叶灬风发布了新的文献求助10
21秒前
微笑完成签到,获得积分10
21秒前
myyyyy完成签到,获得积分10
22秒前
不摸鱼上啥班完成签到,获得积分10
22秒前
hdbys完成签到,获得积分10
22秒前
romeo完成签到,获得积分10
23秒前
28秒前
科研孙一完成签到,获得积分10
29秒前
franklylyly完成签到,获得积分10
29秒前
爱吃菠萝的大葱完成签到,获得积分10
31秒前
Tonald Yang发布了新的文献求助10
31秒前
qing完成签到 ,获得积分10
31秒前
一杯半茶完成签到 ,获得积分10
31秒前
qiuy发布了新的文献求助10
36秒前
陈少华完成签到 ,获得积分10
37秒前
烟火会翻滚完成签到,获得积分10
38秒前
蜡笔小新完成签到 ,获得积分10
40秒前
mimilv完成签到,获得积分10
41秒前
ChengYonghui完成签到,获得积分10
42秒前
知画春秋完成签到 ,获得积分10
43秒前
风一样的我完成签到 ,获得积分0
45秒前
长风完成签到,获得积分10
45秒前
Cuzz完成签到 ,获得积分20
46秒前
善良的冰绿完成签到,获得积分10
47秒前
手握灵珠常奋笔完成签到,获得积分10
48秒前
zh1858f完成签到,获得积分10
48秒前
乐观阑悦完成签到 ,获得积分10
50秒前
枯叶灬风完成签到,获得积分10
51秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180097
求助须知:如何正确求助?哪些是违规求助? 9570230
关于积分的说明 21808841
捐赠科研通 7776113
什么是DOI,文献DOI怎么找? 3433261
关于科研通互助平台的介绍 2557463
邀请新用户注册赠送积分活动 2479013